Two-year outcome after combination therapy for polypoidal choroidal vasculopathy: Comparison with photodynamic monotherapy and anti-vascular endothelial growth factor monotherapy

Ophthalmologica

Volumn 231, Issue 2, 2014, Pages 86-93

  Kang, Hae Min ^a   Koh, Hyoung Jun ^a  

^a Yonsei University College of Medicine   (South Korea)

Author keywords

Anti vascular endothelial growth factor therapy; Combination therapy; Photodynamic therapy; Polypoidal choroidal vasculopathy

Indexed keywords

BEVACIZUMAB; RANIBIZUMAB; VERTEPORFIN;

AGED; ARTICLE; BEST CORRECTED VISUAL ACUITY; CLINICAL EFFECTIVENESS; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PHOTODYNAMIC THERAPY; POLYPOIDAL CHOROIDAL VASCULOPATHY; RETROSPECTIVE STUDY; TREATMENT OUTCOME; VISUAL ACUITY; ATROPHY; CENTRAL RETINAL THICKNESS; CEREBROVASCULAR ACCIDENT; DIODE LASER; DRUG TREATMENT FAILURE; MONOTHERAPY; POLYP; RECURRENT DISEASE; RETINA DISEASE; RETINAL PIGMENT EPITHELIUM ATROPHY; SUBRETINAL FIBROSIS; TREATMENT RESPONSE; VISUAL IMPAIRMENT;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; CHOROID; CHOROID DISEASES; FLUORESCEIN ANGIOGRAPHY; FOLLOW-UP STUDIES; FUNDUS OCULI; INFUSIONS, INTRAVENOUS; INTRAVITREAL INJECTIONS; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; PORPHYRINS; RETROSPECTIVE STUDIES; TIME FACTORS; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY;

EID: 84893646706     PISSN: 00303755     EISSN: 14230267     Source Type: Journal    
DOI: 10.1159/000354546     Document Type: Article

References (37)

1. Yannuzzi LA, Sorenson J, Spaide RF, Lipson B: Idiopathic polypoidal choroidal vasculopathy (IPCV). Retina 1990; 10: 1-8
2. Spaide RF, Yannuzzi LA, Slakter JS, Sorenson J, Orlach DA: Indocyanine green videoangiography of idiopathic choroidal vasculopathy. Retina 1995; 15: 100-110
3. Yannuzzi LA, Ciardella A, Spaide RF, Rabb M, Freund KB, Orlock DA: The expanding clinical spectrum of idiopathic polypoidal choroidal vasculopathy. Arch Ophthalmol 1997; 115: 478-485
4. Yannuzzi LA, Wong DW, Sforzolini BS, Goldbaum M, Tang KC, Spaide RF, Freund KB, Slakter JS, Guyer DR, Sorenson JA, Fisher Y, Maberley D, Orlock DA: Polypoidal choroidal vasculopathy and neovascularized agerelated macular degeneration. Arch Ophthalmol 1999; 117: 1503-1510
5. Imamura Y, Engelbert M, Iida T, Freund KB, Yannuzzi LA: Polypoidal choroidal vasculopathy: A review. Surv Ophthalmol 2010; 55: 501-515
6. Maruko I, Iida T, Saito M, Nagayama D, Saito K: Clinical characteristics of exudative age-related macular degeneration in Japanese patients. Am J Ophthalmol 2007; 144: 15-22
7. Uyama M, Wada M, Nagai Y, Matsubara T, Matsunaga H, Fukushima I, Takahashi K, Matsumura M: Polypoidal choroidal vasculopathy: Natural history. Am J Ophthalmol 2002; 133: 639-648
8. Kang HM, Kim YM, Koh HJ: Five-year follow-up results of photodynamic therapy for polypoidal choroidal vasculopathy. Am J Ophthalmol 2013; 155: 438-447
9. Gomi F, Ohji M, Sayanagi K, Sawa M, Sakaguchi H, Oshima Y, Ikuno Y, Tano Y: One-year outcomes of photodynamic therapy in age-related macular degeneration and polypoidal choroidal vasculopathy in Japanese patients. Ophthalmology 2008; 115: 141-146
10. Chan WM, Lam DS, Lai TY, Liu DT, Li KK, Yao Y, Wong TH: Photodynamic therapy with verteporfin for symptomatic polypoidal choroidal vasculopathy. Ophthalmology 2004; 111: 1576-1584
11. Rouvas AA, Papakostas TD, Ntouraki A, Douvali M, Vergados I, Ladas ID: Photodynamic therapy, ranibizumab, and ranibizumab with photodynamic therapy for the treatment of polypoidal choroidal vasculopathy. Retina 2011; 31: 464-474
12. Saito M, Iida T, Kano M: Combined intravitreal ranibizumab and photodynamic therapy for polypoidal choroidal vasculopathy. Retina 2012; 32: 1272-1279
13. Hirami Y, Tsujikawa A, Otani A, Yodoi Y, Aikawa H, Mandai M, Yoshimura N: Hemorrhagic complications after photodynamic therapy for polypoidal choroidal vasculopathy. Retina 2007; 27: 335-341
14. Ojima Y, Tsujikawa A, Otani A, Hirami Y, Aikawa H, Yoshimura N: Recurrent bleeding after photodynamic therapy in polypoidal choroidal vasculopathy. Am J Ophthalmol 2006; 141: 958-960
15. Tzekov R, Lin T, Zhang KM, Jackson B, Oyejide A, Orilla W, Kulkarni AD, Kuppermann BD, Wheeler L, Burke J: Ocular changes after photodynamic therapy. Invest Ophthalmol Vis Sci 2006; 47: 377-385
16. Wachtlin J, Behme T, Heimann H, Kellner U, Foerster MH: Concentric retinal pigment epithelium atrophy after a single photodynamic therapy. Graefes Arch Clin Exp Ophthalmol 2003; 241: 518-521
17. Shanmugam MP, Agarwal M: RPE atrophy following photodynamic therapy in type 2A idiopathic parafoveal telangiectasis. Indian J Ophthalmol 2005; 53: 61-63
18. Tong JP, Chan WM, Liu DT, Lai TY, Choy KW, Pang CP, Lam DS: Aqueous humor levels of vascular endothelial growth factor and pigment epithelium derived factor in polypoidal choroidal vasculopathy and choroidal neovascularization. Am J Ophthalmol 2006; 141: 456-462
19. Matsuoka M, Ogata N, Otsuji T, Nishimura T, Takahashi K, Matsumura M: Expression of pigment epithelium derived factor and vascular endothelial growth factor in choroidal neovascular membranes and polypoidal choroidal vasculopathy. Br J Ophthalmol 2004; 88: 809-815
20. Gomi F, Sawa M, Sakaguchi H, Tsujikawa M, Oshima Y, Kamei M, Tano Y: Efficacy of intravitreal bevacizumab for polypoidal choroidal vasculopathy. Br J Ophthalmol 2008; 92: 70-73
21. Song JH, Byeon SH, Lee SC, Koh HJ, Kwon OW: Short-Term safety and efficacy of a single intravitreal bevacizumab injection for the management of polypoidal choroidal vasculopathy. Ophthalmologica 2009; 223: 85-92
22. Hikichi T, Higuchi M, Matsushita T, Kosaka S, Matsushita R, Takami K, Ohtsuka H, Ariga H: One-year results of three monthly ranibizumab injections and as-needed reinjections for polypoidal choroidal vasculopathy in Japanese patients. Am J Ophthalmol 2012; 154: 117-124
23. Tsujikawa A, Ooto S, Yamashiro K, Tamura H, Otani A, Yoshimura N: Treatment of polypoidal choroidal vasculopathy by intravitreal injection of bevacizumab. Jpn J Ophthalmol 2010; 54: 310-319
24. Lee YA, Yang CH, Yang CM, Ho TC, Lin CP, Huang JS, Chen MS: Photodynamic therapy with or without intravitreal bevacizumab for polypoidal choroidal vasculopathy: Two years of follow-up. Am J Ophthalmol 2012; 154: 872-880
25. Ahlers C, Golbaz I, Stock G, Fous A, Kolar S, Pruente C, Schmidt-Erfurth UM: Time course of morphologic effects on different retinal compartments after ranibizumab therapy in age-related macular degeneration. Ophthalmology 2008; 115: 39-46
26. Golbaz I, Ahlers C, Stock G, Schutze C, Schriefl S, Schlanitz F, Simader C, Prunte C, Schmidt-Erfurth UM: Quantification of the therapeutic response of intraretinal, subretinal, and subpigment epithelial compartments in exudative AMD during anti-VEGF therapy. Invest Ophthalmol Vis Sci 2011; 52: 1599-1605
27. Cursiefen C, Chen L, Borges LP, Jackson D, Cao J, Radziejewski C, D'Amore PA, Dana MR, Wiegand SJ, Streilein JW: VEGF-A stimulates lymphangiogenesis and hemangiogenesis in inflammatory neovascularization via macrophage recruitment. J Clin Invest 2004; 113: 1040-1050
28. Lafaut BA, Aisenbrey S, van den Broecke C, Bartz-Schmidt KU, Heimann K: Polypoidal choroidal vasculopathy pattern in age-related macular degeneration: A clinicopathologic correlation. Retina 2000; 20: 650-654
29. Okubo A, Sameshima M, Uemura A, Kanda S, Ohba N: Clinicopathological correlation of polypoidal choroidal vasculopathy revealed by ultrastructural study. Br J Ophthalmol 2002; 86: 1093-1098
30. Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N: Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989; 246: 1306-1309
31. Gomi F, Sawa M, Wakabayashi T, Sasamoto Y, Suzuki M, Tsujikawa M: Efficacy of intravitreal bevacizumab combined with photodynamic therapy for polypoidal choroidal vasculopathy. Am J Ophthalmol 2010; 150: 48-54.e1
32. Kim M, Kim K, Kim DG, Yu SY, Kwak HW: Two-year results of photodynamic therapy combined with intravitreal anti-vascular endothelial growth factor for polypoidal choroidal vasculopathy. Ophthalmologica 2011; 226: 205-213
33. Nemoto R, Miura M, Iwasaki T, Goto H: Two-year follow-up of ranibizumab combined with photodynamic therapy for polypoidal choroidal vasculopathy. Clin Ophthalmol 2012; 6: 1633-1638
34. Cho HJ, Kim JW, Lee DW, Cho SW, Kim CG: Intravitreal bevacizumab and ranibizumab injections for patients with polypoidal choroidal vasculopathy. Eye 2012; 26: 426-433
35. Comparison of Age-Related Macular Degeneration Treatments Trials (CATT) Research Group, Martin DF, Maguire MG, Fine SL, Ying GS, Jaffe GJ, Grunwald JE, Toth C, Redford M, Ferris FL 3rd: Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: Two-year results. Ophthalmology 2012; 119: 1388-1398
36. Lai TY, Lee GK, Luk FO, Lam DS: Intravitreal ranibizumab with or without photodynamic therapy for the treatment of symptomatic polypoidal choroidal vasculopathy. Retina 2011; 31: 1581-1588
37. Kim SJ, Yu HG: Efficacy of combined photodynamic therapy and intravitreal bevacizumab injection versus photodynamic therapy alone in polypoidal choroidal vasculopathy. Retina 2011; 31: 1827-1834